Everything below concerns clinical evidence. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
"Alzheimer's Disease Research Timeline – Alzforum". www.alzforum.org. "Alzheimer's Disease Brain Cell Atlas- brain-map.org". portal.brain-map.org. "What's the deal with Alzheimer's disease and amyloid?". For decades, scientists have concentrated on what now looks to be a blind alley. The Amyloid Mafia. Jonathan M. Gitlin, Ars Technica, Apr 15, 2026
=== Immunosuppression === Immunosuppression is used inconsistently in Sydenham's chorea. The model of an autoimmune disorder would support its use. One randomized controlled trial of steroids from Paz, Brazil in 2006 (22 cases) showed remission reduced to 54 days from 119 days. Various other reports of use of oral or IV steroids from Israel, Italy and Brazil. Immunoglobulin has been used in Holland and South Africa. Some improvement can be seen within a few days of IV steroids. In Italy, prednisolone reduced average duration of symptoms from 9 weeks to 4 weeks, and these were severe cases. South African group found less neuropsychiatric complications at 6 months with IVIG treatment (IVIG preferred due to fear of TB reactivation).
Jonathan Vilma, a Saints player who had a major role in the scheme and reportedly offered a $10,000 bounty on Brett Favre, was suspended for the entire season and three other players were suspended for parts of the season. However, in September 2012, an arbitrator overturned the suspensions of the players involved in the affair. Williams' suspension ultimately lasted one year. Deflategate (2015) – during the AFC Championship Game, 11 of the 12 footballs under the Patriots' control during the first half were found to be inflated below the level mandated by the rulebook. The case was then closed because of the referees' failure to check the balls prior to the game. Tom Brady was suspended by the NFL for the first 4 games of the 2016 season.
=== Activation === Asparagine endopeptidase is synthesized as an inactive zymogen. AEP and other cysteine peptidase are activated when pH changes from neutral to acidic. It undergoes autoproteolytic maturation for catalytic activation. It appears to be autocatalytically cleaved after asparagine or aspartate residue. Activation begins at pH 4.5. The chemical structure at this point shows that breaks which occurs at pH 4.5 can be healed under the basic crystallization conditions. C-terminal fragments (≈13 kDa) generated during autoproteolysis can gradually re-ligated to form the proenzyme when the pH is increased towards pH 7.5, which means that proteolytic activation of AEP can be reversible.
as it was in the general continuum equations and in the incompressible flow section. The compressible momentum Navier–Stokes equation results from the following assumptions on the Cauchy stress tensor:
Sources: en.wikipedia.org
== History == EMP was first synthesized in the mid-1960s and was patented in 1967. It was initially developed for the treatment of breast cancer. The idea for EMP was inspired by the uptake and accumulation of radiolabeled estrogens into breast cancer tissue. However, initial clinical findings of EMP in women with breast cancer were disappointing. Subsequently, radiolabeled EMP was found to be taken up into and accumulated rat prostate gland, and this finding culminated in the medication being repurposed for the treatment of prostate cancer. EMP was introduced for medical use in the treatment of this condition in the early 1970s, and was approved in the United States for this indication in 1981. EMP was originally introduced for use by intravenous injection. Subsequently, an oral formulation was introduced, and the intravenous preparation was almost abandoned in favor of the oral version.
== Research == Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. The therapy was used to treat patients with locally recurrent or metastatic breast cancer. Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products.
This technique eliminates pharmacokinetic issues with non-equivalent clearance as well as enabling the intravenous dose to be administered with a minimum of toxicology and formulation. The technique was first applied using stable-isotopes such as 13C and mass-spectrometry to distinguish the isotopes by mass difference. More recently, 14C labelled drugs are administered intravenously and accelerator mass spectrometry (AMS) used to measure the isotopically labelled drug along with mass spectrometry for the unlabelled drug. There is no regulatory requirement to define the intravenous pharmacokinetics or absolute bioavailability however regulatory authorities do sometimes ask for absolute bioavailability information of the extravascular route in cases in which the bioavailability is apparently low or variable and there is a proven relationship between the pharmacodynamics and the pharmacokinetics at therapeutic doses. In all such cases, to conduct an absolute bioavailability study requires that the drug be given intravenously. Intravenous administration of a developmental drug can provide valuable information on the fundamental pharmacokinetic parameters of volume of distribution (V) and clearance (CL).
On 15 January 2021, US Secretary of State Mike Pompeo said that to assist the WHO investigative team's work and ensure a transparent, thorough investigation of COVID-19's origin, the US was sharing new information and urging the WHO to press the Chinese government to address three specific issues, including the illnesses of several researchers inside the WIV in autumn 2019 "with symptoms consistent with both COVID-19 and common seasonal illnesses", the WIV's research on "RaTG13" and "gain of function", and the WIV's links to the People's Liberation Army. On 18 January, the US called on China to allow the WHO's expert team to interview "care givers, former patients and lab workers" in the city of Wuhan, drawing a rebuke from the Chinese government. Australia also called for the WHO team to have access to "relevant data, information and key locations". A classified report from May 2020 by the Lawrence Livermore National Laboratory, a US government national laboratory, concluded that the hypothesis that the virus leaked from the WIV "is plausible and deserves further investigation", although the report also notes that the virus could have developed naturally, echoing the consensus of the American intelligence community, and provides no "smoking gun" towards either hypothesis.
Club considers the duo's collaborations—which earned them the 2013 National Board of Review (Spotlight Award)—to be career-defining moments for both of them and as vital as Scorsese's acclaimed collaborations with Robert De Niro. Author Michael K. Hammond wrote that DiCaprio built his star reputation by demonstrating his acting ability, and praised him for "revealing a character while concealing the actor" and "disappearing into [his] roles". According to Agnieszka Holland, who directed DiCaprio in Total Eclipse (1995), DiCaprio is "one of the most mature actors" she has worked with and is "courageous" in his choice of roles. Holland remarked that he does not rely on method acting but rather on a trick that allows him to truly "become the character". His Marvin's Room co-star Meryl Streep said that DiCaprio possesses the kind of unpredictability that makes his career difficult to classify, his life precarious and his work thrilling. Analyzing DiCaprio's career, film critic Philip French identified a theme of "characters who are still in the process of becoming a man" and suggested that the actor's propensity for films about dysfunctional families and characters seeking father figures alludes to his own troubled childhood. DiCaprio often plays characters who themselves are playing roles, which Caryn James says looks simple on screen but requires sophisticated acting. He tends to play antiheroes and characters who lose their mental stability as the narrative progresses.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.